The genetic tumor background is an important determinant for heterogeneous MYCN‐amplified neuroblastoma

Amplification of MYCN is the signature genetic aberration of 20–25% of neuroblastoma and a stratifying marker associated with aggressive tumor behavior. The detection of heterogeneous MYCN amplification (hetMNA) poses a diagnostic dilemma due to the uncertainty of its relevance to tumor behavior. He...

Descripción completa

Detalles Bibliográficos
Autores principales: Bogen, Dominik, Brunner, Clemens, Walder, Diana, Ziegler, Andrea, Abbasi, Reza, Ladenstein, Ruth L., Noguera, Rosa, Martinsson, Tommy, Amann, Gabriele, Schilling, Freimut H., Ussowicz, Marek, Benesch, Martin, Ambros, Peter F., Ambros, Inge M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Tumor Markers and Signatures
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949549/
https://www.ncbi.nlm.nih.gov/pubmed/26910568
http://dx.doi.org/10.1002/ijc.30050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949549/
https://www.ncbi.nlm.nih.gov/pubmed/26910568
http://dx.doi.org/10.1002/ijc.30050

Ejemplares similares